Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | MGAM | O43451 | 1/20 | 0.41 |
| ▸ | SI | P14410 | 1/20 | 0.41 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.41 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.36 |
| ▸ | MMP8 | P22894 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25746395 | 0.85 | MGAM (0.39) | GAAMGAMSIMGAM2EGLN1 | |
| SCHEMBL8733356 | 0.83 | GAA (0.37) | GAAALDH1A1SMN1; SMN2LMNATSHR | |
| SCHEMBL8804853 | 0.81 | GAA (0.52) | GAAMGAMSIMGAM2EGLN1 | |
| SCHEMBL1667402 | 0.81 | MGAM (0.39) | GAAMGAMSIMGAM2EGLN1 | |
| SCHEMBL7638571 | 0.79 | TET2 (0.38) | EGLN1ALDH1A1TSHRKMT2A | |
| SCHEMBL8283543 | 0.77 | MMP8 (0.46) | GAAMGAMSIMGAM2EGLN1 | |
| SCHEMBL66328 | 0.77 | GAA (0.64) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL16047813 | 0.77 | EGLN1 (0.47) | GAAMGAMSIMGAM2EGLN1 | |
| SCHEMBL17817681 | 0.77 | GAA (0.48) | GAAMGAMSIMGAM2EGLN1 | |
| SCHEMBL27825811 | 0.76 | GAA (0.61) | GAAMGAMSIMGAM2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 151 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4619388-A1 | CATHEPSIN L INHIBITORS | Biofront Therapeutics (Beijing) Co., Ltd. (CN) | 2025-09-24 | — | — | EP | disclosed |
| EP-4267574-B1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | AJAX THERAPEUTICS INC (US) | 2025-04-23 | — | — | EP | disclosed |
| US-12275717-B2 | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors | AJAX THERAPEUTICS, INC. (US) | 2025-04-15 | — | — | US | disclosed |
| US-20240327380-A1 | BTK INHIBITORS | BIOGEN MA INC. (US) | 2024-10-03 | — | — | US | disclosed |
| US-12043632-B2 | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors | AJAX THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| WO-2024140356-A1 | CATHEPSIN L INHIBITORS | BIOFRONT THERAPEUTICS (BEIJING) CO., LTD. (CN) | 2024-07-04 | — | — | WO | disclosed |
| US-20240043436-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2024-02-08 | — | — | US | disclosed |
| US-11858905-B1 | Cathepsin L inhibitors | BIOFRONT THERAPEUTICS (BEIJING) CO., LTD. (CN) | 2024-01-02 | — | — | US | disclosed |
| US-11807644-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| EP-4267574-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. (US) | 2023-11-01 | — | — | EP | disclosed |
| CN-1305478-A | Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction | PFIZER (US) | 2001-07-25 | — | — | CN | disclosed |
| US-6251904-B1 | Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction | PFIZER INC. | 2001-06-26 | — | — | US | disclosed |
| EP-1073658-A1 | PYRAZOLOPYRIMIDINONE CGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION | PFIZER INC. (US) | 2001-02-07 | — | — | EP | disclosed |
| WO-1999054333-A1 | PYRAZOLOPYRIMIDINONE CGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION | PFIZER INC. (US) | 1999-10-28 | — | — | WO | disclosed |
| EP-0693473-B1 | Method of producing pivaloylacetic acid ester | UBE INDUSTRIES (JP) | 1998-04-22 | — | — | EP | disclosed |
| US-5679830-A | DECARBONYLATION OF PIVALOYLPYRUVIC ACID IN THE PRESENCE OF AN INORGANIC OXIDE CATALYST | UBE INDUSTRIES, LTD. (JP) | 1997-10-21 | — | — | US | disclosed |
| EP-0693473-A1 | Method of producing pivaloylacetic acid ester | UBE INDUSTRIES, LTD. (JP) | 1996-01-24 | — | — | EP | disclosed |
| US-4739104-A | Process for the preparation of pivaloylpyruvic acid esters | BAYER AKTIENGESELLSCHAFT (DE) | 1988-04-19 | — | — | US | disclosed |
| US-4661621-A | DECARBONYLATION | BAYER AKTIENGESELLSCHAFT (DE) | 1987-04-28 | — | — | US | disclosed |
| US-4345078-A | Combating arthropods with O-alkyl-O-[5-carbalkoxy-7-alkyl-pyrazolo(1,5-α)-pyrimidin-2-yl]-(thiono) (thiol)-phosphoric (phosphonic) acid esters | BAYER AKTIENGESELLSCHAFT (DE) | 1982-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12275717-B2 | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors | JAK2, JAK3, STAT5B | GAA 2648/4885MGAM 4511/4885SI 4856/4885 |
| US-20240327380-A1 | BTK INHIBITORS | BTK, SYK, LYN | GAA 1724/4885MGAM 3028/4885SI 4184/4885 |
| US-11858905-B1 | Cathepsin L inhibitors | CTSV, CTSL, CTSB | GAA 13/4885MGAM 711/4885SI 97/4885 |
| US-11807644-B2 | Methods and compounds for restoring mutant p53 function | TP53, TP53BP1, HRAS | GAA 2245/4885MGAM 4138/4885SI 4181/4885 |
| US-12043632-B2 | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors | JAK2, JAK3, STAT5B | GAA 2648/4885MGAM 4511/4885SI 4856/4885 |
| US-20240043436-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, HRAS | GAA 2245/4885MGAM 4138/4885SI 4181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.